Harnessing the chemokine system to home CAR-T cells into solid tumors

Jade Foeng; Iain Comerford; Shaun R McColl

doi:10.1016/j.xcrm.2022.100543

Harnessing the chemokine system to home CAR-T cells into solid tumors

Cell Rep Med. 2022 Feb 28;3(3):100543. doi: 10.1016/j.xcrm.2022.100543. eCollection 2022 Mar 15.

Authors

Jade Foeng^{1

2}, Iain Comerford¹, Shaun R McColl^{1

2}

Affiliations

¹ Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, SA 5005, Australia.
² Carina Biotech, Innovation and Collaboration Centre, The University of South Australia, Adelaide, SA 5000, Australia.

Abstract

CAR-T cell therapy has been heralded as a breakthrough in the field of immunotherapy, but to date, this success has been limited to hematological malignancies. By harnessing the chemokine system and taking into consideration the chemokine expression profile in the tumor microenvironment, CAR-T cells may be homed into tumors to facilitate direct tumor cell cytolysis and overcome a major hurdle in generating effective CAR-T cell responses to solid cancers.

Keywords: CAR-T cell therapy; chemokine receptors; immunotherapy; solid tumors.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Chemokines
Humans
Immunotherapy, Adoptive
Neoplasms* / therapy
Receptors, Antigen, T-Cell*
T-Lymphocytes
Tumor Microenvironment

Substances

Chemokines
Receptors, Antigen, T-Cell